Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is focused on developing ribonucleic acid modulator drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. The company is headquartered in Waltham, Massachusetts.